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Abstract
Background: Reversing a neuromuscular blockade agent with sugammadex is known to lessen postoperative
complications by reducing postoperative residual curarization. However, its effects on 90-day mortality are
unknown. Therefore, this study aimed to compare the effects of sugammadex and neostigmine in terms of 90-day
mortality after non-cardiac surgery.
Methods: This retrospective cohort study analyzed the medical records of adult patients aged 18 years or older
who underwent non-cardiac surgery at a single tertiary care hospital between 2011 and 2016. Propensity score
matching and Cox regression analysis were used to investigate the effectiveness of sugammadex and neostigmine
in lowering 90-day mortality after non-cardiac surgery.
Results: A total of 65,702 patients were included in the analysis (mean age: 52.3 years, standard deviation: 15.7), and
23,532 of these patients (35.8%) received general surgery. After propensity score matching, 14,179 patients (3906
patients from the sugammadex group and 10,273 patients from the neostigmine group) were included in the final
analysis. Cox regression analysis in the propensity score-matched cohort showed that the risk of 90-day mortality
was 40% lower in the sugammadex group than in the neostigmine group (hazard ratio: 0.60, 95% confidence
interval: 0.37, 0.98; P = 0.042). These results were similar in the multivariable Cox regression analysis of the entire
cohort (hazard ratio: 0.62, 95% confidence interval: 0.39, 0.96; P = 0.036).
Conclusions: This retrospective cohort study suggested that reversing rocuronium with sugammadex might be
associated with lower 90-day mortality after non-cardiac surgery compared to neostigmine. However, since this
study did not evaluate quantitative neuromuscular function in the postoperative period due to its retrospective
design, the results should be interpreted carefully. Future prospective studies with quantitative neuromuscular
monitoring in the postoperative period should be performed to confirm these results.
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Background
Neuromuscular blocking agents (NMBAs) have enabled
anesthesiologists to achieve optimal surgical conditions, in
which patients are immobilized more easily, using smaller
amounts of inhaled or intravenous anesthetics [1]. Muscle
relaxation with NMBAs has now become part of the clas-
sic triad of anesthesia, along with unconsciousness and
analgesia [2]. However, like most drugs, NMBAs may
cause complications, such as postoperative residual curari-
zation (PORC) [3]. PORC can increase respiratory compli-
cations, which may be life-threatening in the immediate
postoperative period [4], with an incidence as high as
63.5%, as found by Fortier et al., and 64.7% according to
the research by Saager et al. [5, 6].
In 1954, Beecher et al. first reported that the use of
NMBAs is associated with anesthesia-related mortality [7].
Since then, PORC has been shown to increase life-
threatening critical respiratory events in the immediate
postoperative period [8, 9]. In 2017, Bronsert and
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colleagues reported that PORC, caused by large amounts
of NMBAs, may increase 30-day mortality and overall all-
cause mortality after non-cardiac surgery [10], in addition
to causing critical complications in the immediate postop-
erative period [4]. This showed that PORC may affect
mortality over a relatively long term, as well as in the im-
mediate postoperative period. However, their study pri-
marily used the conventional NMBA reversal agent,
neostigmine, and not sugammadex, a newer NMBA rever-
sal agent. Sugammadex is a selective relaxant-binding
agent that quickly and effectively reverses the effects of
steroidal NMBAs, especially rocuronium and vecuronium
[11–13]. Compared with neostigmine, sugammadex more
substantially reduces PORC [14, 15], but its effects on
postoperative mortality requires further investigation.
Therefore, this study aimed to compare the effects of
sugammadex and neostigmine in terms of 90-day mor-
tality after non-cardiac surgery. We hypothesized that
using sugammadex for NMBA reversal would improve
90-day mortality after non-cardiac surgery. We thus in-
vestigated the 90-day mortality after non-cardiac surgery
between sugammadex and neostigmine groups, and also
investigated whether the dosage of sugammadex or neo-
stigmine affected the 90-day mortality after non-cardiac
surgery.
Methods
Design and ethical statement
This retrospective cohort study was approved by the insti-
tutional review board (IRB) of the Seoul National Univer-
sity Bundang Hospital (SNUBH) (Approval number: B-
1809-495-102, approval date: September 7, 2018). Consid-
ering the retrospective nature of the study, in which the
medical records of patients who had already completed
treatment were analyzed, the requirement for obtaining
informed consent was waived by the IRB. This manuscript
adheres to the applicable STROBE guidelines.
Patients
This study analyzed the medical records of adult patients
aged 18 years or older who underwent non-cardiac sur-
gery at SNUBH between January 2011 and December
2016. When a patient underwent two or more surgeries,
only the final surgery was included in the analysis. Add-
itionally, cases involving incomplete or missing medical
records, non-general anesthesia, use of NMBAs other
than rocuronium (e.g., cisatracurium), or no NMBA re-
versal after surgery were excluded from the analysis.
Rocuronium reversal by sugammadex or neostigmine
SNUBH has generally used rocuronium for general
anesthesia in non-cardiac surgeries, while neostigmine or
sugammadex has been used as the agent for NMBA rever-
sal after the end of each surgery. There is no strict
guideline in our institution to determine the agent (sugam-
madex or neostigmine) used for NMBA reversal. The deci-
sion for using sugammadex or neostigmine is made based
on the judgment of the individual anesthesiologist accord-
ing to the type of surgery, the surgery time, the underlying
disease of the patients, and the amount of NMBA used. In
most cases, the dosage of sugammadex or neostigmine for
NMBA reversal was determined after qualitative (subject-
ive) neuromuscular monitoring using two peripheral nerve
stimulators (Innervator 252; Fisher & Paykel Healthcare,
New Zealand, and EZStim II, model ES400; Life-Tech
International, Stafford, Texas). The residual degree of
neuromuscular block from NMBA at emergence was mea-
sured after the end of surgery and before extubation. After
NBMA reversal administration, the train-of-four (TOF)
count was re-checked using the peripheral nerve stimula-
tor to decide on the patient’s readiness for safe extubation.
The dosage of sugammadex was determined by depth of
neuromuscular block at the end of surgery [16]; 2mg/kg
of sugammadex was administered when the TOF count
was ≥1, while 4mg/kg of sugammadex was administered
when the post-tetanic count (PTC) was ≥1. When neostig-
mine was used, the maximum dose (50 mcg/kg) was ad-
ministered for NMBA reversal if the TOF count was 1
[16]. If the TOF count was 2–4 at end of surgery, 30–40
mcg/kg was administered for NMBA reversal in the neo-
stigmine group. Additionally, glycopyrrolate was adminis-
tered with neostigmine to prevent the cholinergic
complications of neostigmine. Intraoperative qualitative
neuromuscular monitoring was performed throughout the
surgery at the discretion of the anesthesiologist. For the
present study, we classified patients who were adminis-
tered sugammadex for NMBA reversal as the sugammadex
group and those who were administered neostigmine as
the neostigmine group.
Covariates
Information regarding the patients’ physical characteris-
tics (age [years], sex, body mass index [kg/m2]); socio-
economic status (insurance type [National Health
Insurance program/Medical Aid Beneficiary program]);
marital status (never married/married or living together/
divorced or separated/widowed); highest educational at-
tainment (lower than high school/more than or equal to
high school, lower than college/more than or equal to
college); occupation (office worker/licensed job/house
work/self-employed/student, military or laborer/un-
employed); and preoperative comorbidities, such as
American Society of Anesthesiologists (ASA) physical
status, hypertension, diabetes mellitus, ischemic heart
disease, cerebrovascular disease, liver disease (fatty liver,
liver cirrhosis, and hepatitis), dyslipidemia, chronic kid-
ney disease, and cancer were recorded. Additionally, op-
erative characteristics such as data regarding surgery and
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anesthesia time (min), emergency surgery, year of sur-
gery, type of non-cardiac surgery (general, thoracic,
neuro or spine, orthopedic, plastic, ear-nose-throat, den-
tal, ophthalmic, gynecologic, or urologic surgery), intra-
operative rocuronium dosage (mg), and intraoperative
qualitative neuromuscular monitoring were collected.
The patients in the Medical Aid Beneficiary program are
those who are classified as having a low income, and
most of their hospital charges are paid by the govern-
ment. For patients in the National Health Insurance pro-
gram, approximately two-thirds of hospital charges are
covered by the government.
Ninety-day mortality after surgery
All cases of death within 90 days from the date of sur-
gery were included in the 90-day mortality calculations.
We obtained the exact dates of death, including for
those patients who were lost to follow-up, from the Min-
istry of the Interior and Safety in South Korea as of De-
cember 31, 2017.
Statistical analysis
Patient characteristics are presented as mean with stand-
ard deviation or number with percentage. First, we per-
formed 1:5 propensity score (PS) matching, a method
used to reduce confounding effects in observational stud-
ies [17]. The Nearest-Neighbor method, without replace-
ment, was used for PS and the matching caliper was set to
0.2. All covariates were included in the PS model, and lo-
gistic regression analysis was performed to calculate PSs,
as a logistic model. To determine the balance between the
two groups before and after PS matching, the absolute
value of the standardized mean difference (ASD) was mea-
sured; ASD < 0.2 was defined as well-balanced. After con-
firming that covariates were well-balanced between the
sugammadex and neostigmine groups after PS matching,
both Cox regression and logistic regression analyses were
performed to investigate the hazard ratio (HR) and odds
ratio (OR) with 95% confidence intervals (CIs) for 90-day
mortality of the sugammadex group as compared to the
neostigmine group in the PS-matched cohort.
Second, we performed uni- and multivariable Cox re-
gression analyses to investigate whether the results from
the PS-matched cohort would be generalizable to the en-
tire cohort in our hospital. Despite this, an understanding
is required of the association between sugammadex rever-
sal and 90-day mortality with other important con-
founders, and not only in isolation. All covariates, except
for duration of anesthesia were included in the multivari-
able Cox regression model to avoid multicollinearity with
duration of surgery. A log minus log plot was used to de-
termine whether the resulting model satisfied the central
assumption of the Cox proportional hazards model. There
was no multi-collinearity among all variables in the
multivariable model with a variance inflation factor < 2.0.
Third, as a secondary sensitivity analysis, we performed
multivariable Cox regression analysis to investigate
whether the dosage of the two NMBA reversal agents
(sugammadex and neostigmine) affected 90-day mortality
in each group. The dosage of sugammadex and neostig-
mine was divided into four groups by quartiles, and all co-
variates were included in the multivariable Cox regression
model (except for duration of surgery). All analyses were
performed using the open-source statistical software R
(version 3.6.1 with R packages); statistical significance was
set at P < 0.05.
Results
Patients
Non-cardiac surgery was performed in 168,731 cases at
our institution between January 2011 and December 2016.
Of these, 41,559 cases were initially excluded from analysis
as two or more surgeries were performed in one patient
during the study period; only the final surgery of each pa-
tient was included in the analysis. Next, patients were ex-
cluded for the following reasons: 1) incomplete medical
records (n = 17,120); 2) non-general anesthesia (n = 34,
675); 3) use of NMBA other than rocuronium (n = 5645);
and 4) no NMBA reversal after surgery (n = 4030). There-
fore, 65,702 patients were included in the final analysis:
4578 in the sugammadex group and 61,124 in the neostig-
mine group. The mean age of the total patients was 52.3
years with a standard deviation of 15.7. Of the total sam-
ple group, 23,532 patients (35.8%) received general sur-
gery. The proportion of patients receiving emergency
surgery was 0.1% (72/65,702). It was further determined
that 34,240 (52.1%) patients were ASA physical status 1
and 29,211 (44.5%) patients were ASA physical status 2.
After 1:5 PS matching, 3906 and 10,273 patients were
isolated in the sugammadex and neostigmine groups,
yielding a total of 14,179 patients (Fig. 1). There is a dif-
ference between the intended matching ratio (1:5) and
actual matching ratio (approximately 1: 2.6) because the
matching algorithm was set to nearest neighbor method
with a caliper of 0.2. The results of a comparison of the
patients’ baseline characteristics before and after PS
matching is presented in Table 1. The ASD between the
two groups after PS matching was well-balanced (ASD <
0.2; Table 1). Figure S1 show that the PS distribution
was similar in the two groups after PS matching. Add-
itionally, the mean sugammadex dosage was 3.24 mg/kg
with a standard deviation of 0.72 mg/kg, and the mean
neostigmine dosage was 30.9 mcg/kg with a standard de-
viation of 9.3 mcg/kg.
Ninety-day mortality after non-cardiac surgery
The results of survival analysis for 90-day mortality be-
fore and after PS matching are presented in Table 2.
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The 90-day mortality in the sugammadex and neostig-
mine group was 0.6% (26/4578) and 0.6% (365/61,124),
respectively, before PS matching in the entire cohort.
The Cox regression and logistic regression models
showed no statistically significant difference in 90-day
mortality between the two groups in the entire cohort
(P = 0.806 and P = 0.804, respectively). However, after PS
matching, the 90-day mortality in the sugammadex
group and neostigmine group was 0.5% (20/3906) and
0.8% (87/10,273), respectively. The Cox regression and
logistic regression models showed that use of sugamma-
dex was associated with a 40% lower 90-day mortality
risk than use of neostigmine (HR: 0.60, 95% CI: 0.37,
0.98; P = 0.042 and OR: 0.60, 95% CI: 0.37, 0.98; P =
0.042). In the multivariable Cox regression model in en-
tire cohort, use of sugammadex was also associated with
38% lower 90-day mortality risk than use of neostigmine
(HR: 0.62, 95% CI: 0.39, 0.96; P = 0.036; Table 3).
Subgroup analysis according to dosage of sugammadex
and neostigmine
Table 4 shows the results of subgroup analysis for 90-
day mortality according to dosage of neostigmine and
sugammadex. In the multivariable Cox regression model
in the neostigmine group, when compared to the Q1
group, the Q2, Q3 and Q4 groups were not associated
with increased 90-day mortality (all P > 0.05). In the
multivariable Cox regression model in the sugammadex
group, when compared to the Q1 group, the Q2, Q3 and
Q4 groups were not associated with increased 90-day
mortality (all P > 0.05).
Discussion
The results of this retrospective cohort study suggested
that reversing rocuronium with sugammadex is associ-
ated with a lower 90-day mortality rate after non-cardiac
surgery when compared with neostigmine. This associ-
ation was statistically significant in the PS-matched co-
hort, but not in the entire cohort. Additionally, the
dosage of sugammadex or neostigmine in both groups
was not associated with 90-day mortality in subgroup
analyses.
The 90-day mortality rate (0.6%) after surgery was
relatively lower in this study than that reported in a
previous study (4% hospital mortality after surgery)
[18]. This difference might be caused by the charac-
teristics of the surgical population of our study. We
excluded relatively high-risk patients who underwent
Fig. 1 Flow chart of patient selection
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Table 1 Comparison between sugammadex group and neostigmine group before and after propensity score matching
Variables Before PS matching (n = 65,702) After PS matching (n = 14,179)
Sugammadex Neostigmine ASD Sugammadex Neostigmine ASD
n = 4578 n = 61,124 n = 3906 n = 10,273
Age, yr 57.7 (14.3) 51.8 (15.7) 0.41 57.2 (14.5) 55.1 (14.9) 0.10
Sex: male 2738 (59.8) 26,517 (43.4) 0.34 2269 (58.1) 5045 (49.1) 0.14
Body mass index, kg m−2 24.2 (3.5) 24.0 (3.4) 0.06 24.1 (3.5) 24.0 (3.4) 0.01
Insurance type 0.03 < 0.01
National health insurance program 4488 (98.0) 59,706 (97.7) 3822 (97.8) 10,045 (97.8)
Medical aid beneficiary program 90 (2.0) 1418 (2.3) 84 (2.2) 228 (2.2)
Marital status 0.14 0.04
Never married 268 (5.9) 6892 (11.3) 230 (5.9) 784 (7.6)
Married or living together 3965 (86.6) 49,956 (81.7) 3379 (86.5) 8722 (84.9)
Divorced or separated 119 (2.6) 1698 (2.8) 104 (2.7) 268 (2.6)
Widowed 226 (4.9) 2578 (4.2) 193 (4.9) 499 (4.9)
Highest educational attainment 0.07 0.03
Lower than high school 1066 (23.3) 13,464 (22.0) 903 (23.1) 2219 (21.6)
More than or equal to high school, lower than college 1434 (31.3) 21,193 (34.7) 1235 (31.6) 3340 (32.5)
More than or equal to college 2078 (45.4) 26,467 (43.3) 1768 (45.3) 4714 (45.9)
Occupation 0.19 0.09
Office worker 943 (20.6) 10,838 (17.7) 804 (20.6) 1988 (19.4)
Licensed job 448 (9.8) 6188 (10.1) 378 (9.7) 1046 (10.2)
House work 1099 (24.0) 19,753 (32.3) 962 (24.6) 2996 (29.2)
Self-employed 668 (14.6) 7114 (11.6) 550 (14.1) 1325 (12.9)
Student, military, or laborer 454 (9.9) 8954 (14.6) 384 (9.8) 1150 (11.2)
Unemployed 966 (21.1) 8277 (13.5) 828 (21.2) 1768 (17.2)
Preoperative comorbidities
ASA physical status 0.20 0.07
1 1891 (41.3) 32,349 (52.9) 1632 (41.8) 4814 (46.9)
2 2489 (54.4) 26,722 (43.7) 2103 (53.8) 5044 (49.1)
3 196 (4.3) 2001 (3.3) 169 (4.3) 410 (4.0)
≥ 4 2 (0.0) 52 (0.1) 2 (0.1) 5 (0.0)
Hypertension 1299 (28.4) 13,402 (21.9) 0.14 1099 (28.1) 2519 (24.5) 007
Diabetes mellitus 567 (12.4) 5611 (9.2) 0.09 482 (12.3) 1120 (10.9) 0.02
Ischemic heart disease 262 (5.7) 2426 (4.0) 0.08 229 (5.9) 531 (5.2) 0.03
Cerebrovascular disease 205 (4.5) 2130 (3.5) 0.05 182 (4.7) 418 (4.1) 0.04
Liver disease (fatty liver, hepatitis, liver cirrhosis) 168 (3.7) 1405 (2.3) 0.07 142 (3.6) 310 (3.0) < 0.01
Dyslipidemia 35 (0.8) 596 (1.0) 0.02 32 (0.8) 90 (0.9) < 0.01
Chronic kidney disease 14 (0.3) 204 (0.3) < 0.01 14 (0.4) 51 (0.5) 0.01
Cancer 2695 (58.9) 18,651 (30.5) 0.58 2242 (57.4) 5080 (49.5) < 0.01
Operative Characteristics
Surgery time, min 150.7 (95.1) 111.8 (145.6) 0.39 148.6 (99.4) 131.4 (102.2) 0.05
Anesthesia time, min 190.8 (104.8) 150.7 (95.1) 0.38 188.3 (105.4) 169.6 (109.0) 0.04
Emergency surgery 3 (0.1) 69 (0.1) 0.02 2 (0.1) 8 (0.1) 0.01
Type of non-cardiac surgery 1.23 0.08
General surgery 3185 (69.6) 20,347 (33.3) 2777 (71.1) 5889 (57.3)
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cardiac surgery, and patients who did not receive
NMBA reversal in order to receive mechanical venti-
lation in the intensive care unit (ICU) during the im-
mediate postoperative period. Additionally, the
patients with end-stage renal disease might have been
excluded from this study, because they usually re-
ceived atracurium or cisatracurium, rather than rocur-
onium, during surgery.
When interpreting the present findings, consideration
must be given to the fact that both quantitative and
qualitative neuromuscular function monitoring was not
routine practice, it was performed at the discretion of
the attending anesthesiologists. Hence, our data reflects
the results of our everyday clinical practice rather than
standardized best practice. Previous surveys also have
shown the limited use of a neuromuscular monitoring,
the majority of which comprised qualitative monitoring,
while the use of quantitative monitoring was far less
common [19–21]. In this study, we measured the TOF
count after surgery at emergence using qualitative ra-
ther than quantitative neuromuscular monitoring, be-
cause quantitative neuromuscular monitoring at the
end of surgery was not available during the study
period (2011–2016). Given that quantitative and object-
ive neuromuscular monitoring is considered the gold
standard to detect PORC [3, 22], the use of qualitative
and subjective neuromuscular monitoring may have af-
fected the results of this study. Although we did not
have access to postoperative TOF ratio data, we assume
that PORC would have been more frequently associated
with neostigmine compared to sugammadex for several
reasons. The ability of neostigmine to reverse neuro-
muscular blockade is limited. Even when the full rec-
ommended dose of 70 mcg/kg is administered at a TOF
count of 4, the recovery has been shown to be unsatis-
factory [23, 24]. Additionally, neostigmine overdose in
Table 1 Comparison between sugammadex group and neostigmine group before and after propensity score matching (Continued)
Variables Before PS matching (n = 65,702) After PS matching (n = 14,179)
Sugammadex Neostigmine ASD Sugammadex Neostigmine ASD
n = 4578 n = 61,124 n = 3906 n = 10,273
Thoracic surgery 40 (0.9) 2974 (4.9) 40 (1.0) 214 (2.1)
Neuro or spine surgery 81 (1.8) 6552 (10.7) 81 (2.1) 461 (4.5)
Orthopedic surgery 52 (1.1) 8654 (14.2) 52 (1.3) 440 (4.3)
Plastic, ENT, Dental, Eye surgery 102 (2.2) 10,458 (17.1) 128 (3.0) 639 (6.2)
Gynecologic or Urologic surgery 1128 (24.5) 12,139 (19.9) 838 (21.5) 2630 (25.6)
Intraoperative rocuronium dosage, mg 1.26 0.02
< 50 3 (0.1) 130 (0.2) 3 (0.1) 11 (0.1)
50–100 1082 (23.6) 47,049 (77.0) 1080 (27.6) 5145 (50.1)
> 100 3493 (76.3) 13,945 (22.8) 2823 (72.3) 5117 (49.8)
Intraoperative qualitative neuromuscular monitoring 78 (1.7) 1.199 (2.0) 0.02 57 (1.5) 128 (1.2) 0.01
Year of surgery 1.83 0.09
2011–2012 0 (0.0) 22,198 (36.3) 0 (0.0) 776 (7.6)
2013–2014 475 (10.4) 18,215 (29.8) 475 (12.2) 2156 (21.0)
2015–2016 4103 (89.6) 20,711 (33.9) 3431 (87.8) 7341 (71.5)
Presented as number (percentage) or mean (standard deviation)
PS propensity score; ASD Absolute value of standardized mean difference; ASA American Society of Anesthesiologists; TOF train-of-four
Table 2 Survival analysis for 90-day mortality before and after propensity score matching
Model Event (%) Cox regression analysis Logistic regression analysis
Hazard ratio (95% CI) P-value Odds ratio (95% CI) P-value
Before propensity score matching
Neostigmine group 365 / 61,124 (0.6%) 1
Sugammadex group 26 / 4578 (0.6%) 0.95 (0.64, 1.42) 0.806 0.95 (0.64, 1.42) 0.804
After propensity score matching
Neostigmine group 87/10,273 (0.8%) 1 1
Sugammadex group 20/3906 (0.5%) 0.60 (0.37, 0.98) 0.042 0.60 (0.37, 0.98) 0.042
CI confidence interval
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Table 3 Univariable and multivariable Cox regression model for 90-day mortality in entire cohorts
Model Univariable model Multivariable modela
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age, yr 1.07 (1.06, 1.08) < 0.001 1.03 (1.02, 1.04) < 0.001
Sex: male (vs female) 2.34 (1.90, 2.88) < 0.001 1.81 (1.34, 2.43) < 0.001
Body mass index, kg m−2 0.80 (0.78, 0.83) < 0.001 0.83 (0.80, 0.85) < 0.001
Insurance type: Medical aid beneficiary program 2.93 (1.95, 4.39) < 0.001 1.30 (0.85, 1.98) 0.229
Marital status
Never married 1 (< 0.001) 1 (0.191)
Married or living together 1.80 (1.19, 2.73) 0.005 0.60 (0.37, 0.97) 0.038
Divorced or separated 1.31 (0.59, 2.92) 0.504 0.52 (023, 1.19) 0.119
Widowed 3.63 (2.16, 6.13) < 0.001 0.56 (0.31, 1.04) 0.065
Highest educational attainment
Lower than high school 1 (< 0.001) 1 (0.056)
More than or equal to high school, lower than college 0.42 (0.33, 0.54) < 0.001 0.79 (0.61, 1.02) 0.065
More than or equal to college 0.35 (0.28, 0.45) < 0.001 0.75 (0.58, 0.97) 0.027
Occupation
Office worker 1 (< 0.001) 1 (0.076)
Licensed job 0.84 (0.46, 1.51) 0.553 0.88 (0.49, 1.60) 0.677
House work 1.36 (0.91, 2.03) 0.129 1.19 (0.74, 1.91) 0.467
Self-employed 1.43 (0.88, 2.31) 0.150 0.91 (0.56, 1.49) 0.716
Student, military, or labourer 1.81 (1.67, 2.80) 0.008 1.07 (0.68, 1.68) 0.778
Unemployed 6.73 (4.66, 7.91) < 0.001 1.47 (0.98, 2.21) 0.063
ASA physical status
1 1 (< 0.001) 1 (< 0.001)
2 7.73 (5.42, 11.03) < 0.001 5.38 (3.69, 7.91) < 0.001
3 54.56 (37.43, 79.53) < 0.001 21.56 (14.02, 33.16) < 0.001
≥ 4 138.51 (61.52, 311.82) < 0.001 42.44 (17.89, 100.66) < 0.001
Hypertension 1.71 (1.39, 2.11) < 0.001 0.66 (0.52, 0.83) < 0.001
Diabetes mellitus 2.29 (1.78, 2.95) < 0.001 0.97 (0.75, 1.27) 0.824
Ischemic heart disease 3.87 (2.91, 5.14) < 0.001 0.90 (0.66, 1.23) 0.509
Cerebrovascular disease 3.02 (2.17, 4.21) < 0.001 0.90 (0.64, 1.27) 0.546
Liver disease (fatty liver, hepatitis, liver cirrhosis) 2.56 (1.68, 3.90) < 0.001 1.81 (1.18, 2.76) 0.006
Dyslipidemia 3.28 (1.85, 5.82) < 0.001 1.20 (0.67, 2.15) 0.540
Chronic kidney disease 8.95 (4.91, 16.30) < 0.001 1.89 (1.02, 3.52) 0.045
Cancer 5.27 (4.23, 6.56) < 0.001 3.32 (2.64, 4.17) < 0.001
Surgery time, hour 1.01 (1.01, 1.02) < 0.001 1.01 (1.01, 1.02) < 0.001
Anesthesia time, hour 1.27 (1.22, 1.32) < 0.001
Emergency surgery 2.36 (0.33, 16.78) 0.392 1.32 (0.20, 10.28) 0.727
Type of non-cardiac surgery
General surgery 1 (< 0.001) 1 (0.007)
Thoracic surgery 2.14 (1.53, 2.99) < 0.001 1.36 (0.97, 1.92) 0.079
Neuro or spine surgery 1.04 (0.75, 1.43) 0.832 1.99 (1.38, 2.85) < 0.001
Orthopedic surgery 0.65 (0.46, 0.93) 0.017 1.41 (0.97, 2.04) 0.074
Plastic, Ear-nose-throat, Dental, Eye surgery 0.54 (0.38, 0.77) 0.001 1.31 (0.91, 1.88) 0.150
Gynecologic or Urologic surgery 0.67 (0.50, 0.90) 0.008 1.04 (0.77, 1.42) 0.785
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fully recovered patients could result in a reduction of
muscle strength.
The contribution of PORC to increased postoperative
mortality and morbidity has been well-documented in
the literature. In a large retrospective study in 2005,
Arbous and colleagues reported that inadequate NMBA
reversal is an independent risk factor for increased 24-h
postoperative mortality and morbidity [25]. Furthermore,
Murphy and colleagues reported that residual block in-
creases life-threatening, critical respiratory events in the
postoperative recovery room [9]. Bronsert and colleagues
were the first to show that PORC caused by NMBA may
affect complications in the immediate postoperative
period, as well as long-term mortality after non-cardiac
surgery [10]. However, they used data from five Veterans
Health Administration hospitals in the United States,
from 2003 to 2008; sugammadex was only approved by
the Food and Drug Administration in the United States
in December 2015. Thus, Bronsert and colleagues were
unable to consider the effect of sugammadex. In con-
trast, our institution (SNUBH) has consistently used
sugammadex as a drug for NMBA reversal since 2011.
Thus, our study presents novel data in that we have de-
scribed the effects of sugammadex on 90-day mortality
after non-cardiac surgery.
A recently published study on the post-anesthesia pul-
monary complications after use of muscle relaxants
(POPULAR) trial reported that use of NMBA in general
anesthesia is associated with a risk of postoperative pul-
monary complications (PPCs), while NMBA reversal
with sugammadex was not significantly associated with
PPCs [26]. The results of the POPULAR trial differed
from those in our study, and the difference could be ex-
plained by a human factor of the anesthetist, because ap-
proximately one-third of patients who underwent
NMBA monitoring were extubated at a TOF ratio < 0.9.
In this context, reversal of sugammadex was independ-
ently associated with a better safety profile. Additionally,
two recent meta-analyses concluded that sugammadex
not only reversed residual NMBA more rapidly and
completely by encapsulation than did the anticholines-
terase reversal drug (neostigmine), but it was also associ-
ated with a better safety profile, specifically regarding
residual NMBA after reversal [27, 28]. The meta-analysis
Table 3 Univariable and multivariable Cox regression model for 90-day mortality in entire cohorts (Continued)
Model Univariable model Multivariable modela
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Year of surgery
2011–2012 1 (0.238) 1 (0.076)
2013–2014 0.95 (0.74, 1.21) 0.672 0.94 (0.73, 1.21) 0.622
2015–2016 0.82 (0.65, 1.04) 0.099 0.75 (0.58, 0.97) 0.029
Intraoperative qualitative neuromuscular monitoring 0.05 (0.00, 1.19) 0.064 0.00 (0.00-) 0.893
Intraoperative Rocuronium dosage, per 1 mg kg−1 1.54 (1.39, 1.70) < 0.001 1.00 (0.97, 1.03) 0.772
Reversal by Sugammadex (vs neostigmine) 0.95 (0.64, 1.42) 0.806 0.62 (0.39, 0.96) 0.036
a All covariates were included in multivariable model, except for surgery time to avoid multi-collinearity in multivariable Cox regression model
CI confidence interval; ASA American Society of Anesthesiologists; TOF train-of-four
Table 4 Subgroup analysis for 90-day mortality according to dosage of neostigmine and sugammadex
Variable Multivariable Cox regression model P-
valueHazard ratio (95% CI)
Neostigmine dosage, mcg kg− 1 (n = 61,124)
Q1 < 27.5 (n = 15,108) 1
27.5≤Q2 < 31.8 (n = 15,464) 0.75 (0.53, 1.06) 0.102
31.8≤Q3 < 36.4 (n = 15,582) 0.89 (0.63, 1.25) 0.491
36.4≤Q4 (n = 14,970) 0.96 (0.66, 1.42) 0.853
Sugammadex dosage, mg kg−1 (n = 4578)
Q1 < 2.8 (n = 1214) 1
2.8≤Q2 < 3.1 (n = 963) 0.94 (0.11, 7.78) 0.955
3.1≤Q3 < 3.6 (n = 1278) 2.27 (0.34, 15.15) 0.397
3.6≤Q4 (n = 1123) 2.91 (0.30, 27.91) 0.354
All covariates were included in the multivariable model
CI confidence interval
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reported that reversal by sugammadex might lead to a
lower incidence of residual NMBA, and related side-
effects, than reversal by neostigmine.
Some plausible mechanisms have been suggested to
explain why PORC could result in an increase of vari-
ous complications beyond the immediate postoperative
period [29]. First, PORC and NMBA reversal with
high-dose neostigmine is known to be associated with
development of hypopharyngeal weakness [30, 31],
which could lead to a risk of aspiration and pneumonia,
and overall higher rates of PPCs [26, 32, 33]. Further-
more, we recently published an observational study in
which we showed that NMBA reversal by sugammadex
was associated with lower 30-day unplanned readmis-
sion rates, hospital charges, and length of hospital stay
after major abdominal surgery [34]. In this study, we
showed that reversal by sugammadex, which might be
closely related to reduced PORC, could have relatively
long-term effects on outcome, beyond the immediate
postoperative period. Second, NMBA reversal with
neostigmine and anticholinesterases might be associ-
ated with increased risk of cardiovascular complica-
tions in the high-risk group (age > 70 years, undergoing
vascular surgery, prior history of atrial fibrillation) [29,
35]. Furthermore, a recent cohort study reported that
PORC in the post-anesthesia care unit is associated
with higher rates of ICU admission [36]. Therefore, the
results of our current study suggested that efforts to
minimize PORC using sugammadex could result in im-
provement of fatal outcomes, such as 90-day mortality.
The results of subgroup analyses regarding dosage of
neostigmine and sugammadex were also notable in this
study. Although the results of the main analysis showed
that sugammadex might be potentially beneficial in
lowering 90-day mortality, the results of subgroup ana-
lyses showed that the dosage of sugammadex or neo-
stigmine did not affect 90-day mortality in either group.
In our institution, the dosage of neostigmine (30–50
mcg/kg) or sugammadex (2–4 mg/kg) was determined
following the surgical procedure using a peripheral
nerve stimulator, in most cases. These results suggested
that although the sugammadex group was associated
with a lower 90-day mortality than the neostigmine
group, the dosage of the agent received in both groups
did not affect the 90-day mortality. This may be be-
cause the TOF count was checked after surgery in most
cases in order to determine the required dosage of neo-
stigmine or sugammadex.
It is possible that the dosage of the agent received in
the neostigmine and sugammadex groups affected the
results of the main analysis. 2 mg/kg of sugammadex
was administered when the TOF count was ≥1, and 4
mg/kg of sugammadex was administered when the
PTC was ≥1. In the neostigmine group, the maximum
dose of neostigmine (50 mcg/kg) was used for NMBA
reversal if the TOF count was 1 (i.e. a moderate block)
at the end of surgery in this study. While doses of
sugammadex lower than 2.0 mg/kg can be sufficient to
reverse residual rocuronium-induced neuromuscular
block with a TOF ratio of 0.2, even 70 mcg/kg of neo-
stigmine cannot reliably reverse a residual neuromus-
cular block with a TOF ratio of 0.2 within 10 min [37].
This suggests that the administration of 50 mcg/kg of
neostigmine in this study might have been an insuffi-
cient dose to reverse a block with a TOF count of 1
without quantitative monitoring [23, 24]. Therefore,
the variation of doses in the sugammadex and the neo-
stigmine groups may not be equipotent, and in the ab-
sence of quantitative monitoring, it is possible that the
neostigmine group in this study was reversed and extu-
bated using a suboptimal dose of neostigmine.
Our study had a few limitations. First, due to the
retrospective nature of the study, the quality and ac-
curacy of the data may not meet the standard re-
quired for prospective studies. Second, this is a single
center study, which limits the generalizability of the
findings. Third, the sugammadex group comprised
only 7.0% of the entire cohort; thus, the sample size
was substantially reduced after propensity score
matching. Fourth, we did not evaluate the PORC at
PACU admission in this study, which could limit the
results of this study. Fifth, we could not provide in-
formation regarding the patients who suffered from
PPCs, due to the retrospective nature of the study.
Additionally, we did not provide information regard-
ing the causes of 90-day mortality in this study.
Lastly, quantitative neuromuscular monitoring was
not performed in the study period at emergence after
surgery to determine the type or dosage of NMBA re-
versal agent. Only qualitative neuromuscular monitor-
ing was performed; however, qualitative monitoring-
guided neostigmine reversal is no longer recom-
mended due to the risk of PORC [3, 22, 38]. There-
fore, our results might have differed if quantitative
monitoring was performed to guide the dosage of
neostigmine; further study is needed to confirm this.
Conclusions
This retrospective study showed that the use of
sugammadex for rocuronium reversal is associated
with a reduced 90-day mortality after non-cardiac
surgery. However, since this study did not evaluate
quantitative neuromuscular function in the postopera-
tive period due to its retrospective design, the results
should be interpreted carefully. Future prospective
studies with quantitative neuromuscular monitoring
in the postoperative period should be performed to
confirm this association.
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